IFNL4基因型和其他个人特征,以预测对长期型肝炎C的基于索福斯布维尔的8周治疗反应
Thomas R O'Brien1, David J Witt2, Varun Saxena3
1Infections and Immunoepidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, United States.
The Journal of infection
|August 31, 2024
概括
较短的型肝炎病毒 (HCV) 治疗显示出高的成功率. 使用祖先,年龄和性别的预测模型可以识别可能在8周的治疗方案中获得治疗成功的个体.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 病毒学 病毒学
- 遗传学 遗传学 是一个
背景情况:
- 对型肝炎病毒 (HCV) 进行更短时间的治疗可以降低成本并增加患者的治疗机会.
- 确定治疗成功的因素对于优化HCV治愈率至关重要.
研究的目的:
- 为了确定与治疗反应相关的因素,在为期8周的索福斯布维尔治疗HCV后.
- 开发一个预测模型,以预测HCV患者个体治疗的成功.
主要方法:
- 对2907名接受为期8周的勒迪帕斯维尔/索福斯布维尔治疗的患者进行分析.
- 基于人口统计,临床特征和IFNL4基因型的失败率的评估.
- 使用祖先,年龄和性别开发治疗反应模型.
主要成果:
- 整体治疗失败率为4.4%.
- 在50岁以下的患者,女性,IFNL4-TT/TT基因型携带者,低病毒载量或HCV基因型-1B感染中观察到较低的失败率.
- 预测治疗失败率在0.5%至8.5%之间,这取决于祖先,年龄和性别.
结论:
- 利用祖先,年龄和性别的算法可以预测HCV治疗失败.
- 该模型的临床应用可能有助于全球消除HCV的努力,特别是在资源有限的环境中.
相关概念视频
Factors Affecting Drug Response: Overview
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Inhibitors of Viral Protein Synthesis
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...


